Skip to main content

Table 2 Comparison of Provider-Perceived Efficacy of Extended-Release Naltrexone vs. Methadone. Detailed Table Summary: Respondents believed that methadone, to a greater degree than extended-release naltrexone, decreases opioid cravings (paired t [38]=3.759, p = 0.000), decreases risk of fatal opioid-overdose death (paired t [40]=2.349, p = 0.023), decreases return to opioid misuse (paired t [39]=2.780, p = 0.008), and works well in patients with co-occurring mental health disorders (paired t [39]=2.322, p = 0.024)

From: A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Perceptions Methadone Naltrexone t df Mean of the Difference Cohen’s d 95% Confidence Interval p
n Mean (SD) n Mean (SD) Lower Upper
MOUD decreases risk of death from opioid overdose 51 4.078 (0.935) 51 3.745 (0.913) −2.349 50 − 0.333 0.360 − 0.618 − 0.048 0.023*
MOUD decreases cravings for opioids 52 4.308 (0.853) 52 3.577 (1.126) −3.759 51 −0.731 0.732 −1.121 − 0.341 0.000*
MOUD decreases rates of relapse 50 4.200 (0.808) 50 3.820 (0.774) −2.780 49 −0.380 0.480 −0.655 − 0.105 0.008*
MOUD works well in patients with co-occurring mental health disorders 50 4.200 (0.857) 50 3.780 (0.954) −2.322 49 −0.420 0.463 −0.784 − 0.057 0.024*
MOUD should be supplemented by mental health counseling 55 4.527 (0.790) 55 4.382 (0.850) −1.343 54 −0.146 0.177 −0.363 0.072 0.185
MOUD should be supplemented by participation in peer support groups 56 4.304 (0.933) 56 4.179 (1.046) −1.475 55 −0.125 0.126 −0.295 0.045 0.146
MOUD efficacy is improved by adding mental health counseling 55 4.309 (1.052) 55 4.418 (0.832) 0.973 54 0.109 0.115 −0.116 0.334 0.335
  1. Notes: MOUD medication for opioid use disorder. Questions asked about the MOUDs extended-release naltrexone and methadone were compared using paired samples t- tests (alpha = 0.05, two-tailed level). * indicates significance at the α = .05 level